Publications by authors named "Vivien D Menkhoff"
Article Synopsis
- In the context of multiple myeloma, CAR T cells targeting B cell maturation antigen (BCMA) show promise for long-term disease management, with various constructs being tested for efficacy.* -
- The study explored the impact of different CAR designs, specifically varying linker lengths and costimulatory domains, on the performance of anti-BCMA CAR T cells using primary T cells and myeloma cell lines.* -
- Results indicated that while the short linker CAR had better cytokine production, the CD28-based CARs outperformed in cytotoxicity and faster killing of MM cells, but the 41BB-based CARs exhibited better persistence in vivo, highlighting the complexity of optimizing CAR architectures.*
The clinical application of chimeric antigen receptor (CAR) T-cell therapy has rapidly changed the treatment options for terminally ill patients with defined blood-borne cancer types. However, CAR T-cell therapy can lead to severe therapy-associated toxicities including CAR-related hematotoxicity, ON-target OFF-tumor toxicity, cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Just as CAR T-cell therapy has evolved regarding receptor design, gene transfer systems and production protocols, the management of side effects has also improved.
View Article and Find Full Text PDF